Cargando…
Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
Calcium-permeable pores formed by small oligomers of amyloid proteins are the primary pathologic species in Alzheimer’s and Parkinson’s diseases. However, the molecular mechanisms underlying the assembly of these toxic oligomers in the plasma membrane of brain cells remain unclear. Here we have anal...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926208/ https://www.ncbi.nlm.nih.gov/pubmed/27352802 http://dx.doi.org/10.1038/srep28781 |
_version_ | 1782440067696951296 |
---|---|
author | Di Scala, Coralie Yahi, Nouara Boutemeur, Sonia Flores, Alessandra Rodriguez, Léa Chahinian, Henri Fantini, Jacques |
author_facet | Di Scala, Coralie Yahi, Nouara Boutemeur, Sonia Flores, Alessandra Rodriguez, Léa Chahinian, Henri Fantini, Jacques |
author_sort | Di Scala, Coralie |
collection | PubMed |
description | Calcium-permeable pores formed by small oligomers of amyloid proteins are the primary pathologic species in Alzheimer’s and Parkinson’s diseases. However, the molecular mechanisms underlying the assembly of these toxic oligomers in the plasma membrane of brain cells remain unclear. Here we have analyzed and compared the pore-forming capability of a large panel of amyloid proteins including wild-type, variant and truncated forms, as well as synthetic peptides derived from specific domains of Aβ1-42 and α-synuclein. We show that amyloid pore formation involves two membrane lipids, ganglioside and cholesterol, that physically interact with amyloid proteins through specific structural motifs. Mutation or deletion of these motifs abolished pore formation. Moreover, α-synuclein (Parkinson) and Aβ peptide (Alzheimer) did no longer form Ca(2+)-permeable pores in presence of drugs that target either cholesterol or ganglioside or both membrane lipids. These results indicate that gangliosides and cholesterol cooperate to favor the formation of amyloid pores through a common molecular mechanism that can be jammed at two different steps, suggesting the possibility of a universal therapeutic approach for neurodegenerative diseases. Finally we present the first successful evaluation of such a new therapeutic approach (coined “membrane therapy”) targeting amyloid pores formed by Aβ1-42 and α-synuclein. |
format | Online Article Text |
id | pubmed-4926208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49262082016-07-01 Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein Di Scala, Coralie Yahi, Nouara Boutemeur, Sonia Flores, Alessandra Rodriguez, Léa Chahinian, Henri Fantini, Jacques Sci Rep Article Calcium-permeable pores formed by small oligomers of amyloid proteins are the primary pathologic species in Alzheimer’s and Parkinson’s diseases. However, the molecular mechanisms underlying the assembly of these toxic oligomers in the plasma membrane of brain cells remain unclear. Here we have analyzed and compared the pore-forming capability of a large panel of amyloid proteins including wild-type, variant and truncated forms, as well as synthetic peptides derived from specific domains of Aβ1-42 and α-synuclein. We show that amyloid pore formation involves two membrane lipids, ganglioside and cholesterol, that physically interact with amyloid proteins through specific structural motifs. Mutation or deletion of these motifs abolished pore formation. Moreover, α-synuclein (Parkinson) and Aβ peptide (Alzheimer) did no longer form Ca(2+)-permeable pores in presence of drugs that target either cholesterol or ganglioside or both membrane lipids. These results indicate that gangliosides and cholesterol cooperate to favor the formation of amyloid pores through a common molecular mechanism that can be jammed at two different steps, suggesting the possibility of a universal therapeutic approach for neurodegenerative diseases. Finally we present the first successful evaluation of such a new therapeutic approach (coined “membrane therapy”) targeting amyloid pores formed by Aβ1-42 and α-synuclein. Nature Publishing Group 2016-06-29 /pmc/articles/PMC4926208/ /pubmed/27352802 http://dx.doi.org/10.1038/srep28781 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Di Scala, Coralie Yahi, Nouara Boutemeur, Sonia Flores, Alessandra Rodriguez, Léa Chahinian, Henri Fantini, Jacques Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein |
title | Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein |
title_full | Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein |
title_fullStr | Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein |
title_full_unstemmed | Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein |
title_short | Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein |
title_sort | common molecular mechanism of amyloid pore formation by alzheimer’s β-amyloid peptide and α-synuclein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926208/ https://www.ncbi.nlm.nih.gov/pubmed/27352802 http://dx.doi.org/10.1038/srep28781 |
work_keys_str_mv | AT discalacoralie commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein AT yahinouara commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein AT boutemeursonia commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein AT floresalessandra commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein AT rodriguezlea commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein AT chahinianhenri commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein AT fantinijacques commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein |